Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia
Pascal Bonaventure, Jonathan Shelton, Sujin Yun, et al.
Journal of Pharmacology and Experimental Therapeutics (2015) Vol. 354, Iss. 3, pp. 471-482
Open Access | Times Cited: 71

Showing 1-25 of 71 citing articles:

Drugs for Insomnia beyond Benzodiazepines: Pharmacology, Clinical Applications, and Discovery
Tobias Atkin, Stefano Comai, Gabriella Gobbi
Pharmacological Reviews (2018) Vol. 70, Iss. 2, pp. 197-245
Open Access | Times Cited: 306
Hypocretins (orexins): The ultimate translational neuropeptides
Laura H. Jacobson, Daniël Hoyer, Luı́s de Lecea
Journal of Internal Medicine (2022) Vol. 291, Iss. 5, pp. 533-556
Closed Access | Times Cited: 71
The Discovery of Suvorexant, the First Orexin Receptor Drug for Insomnia
Paul J. Coleman, Anthony L. Gotter, W. Joseph Herring, et al.
The Annual Review of Pharmacology and Toxicology (2016) Vol. 57, Iss. 1, pp. 509-533
Closed Access | Times Cited: 114
In Vitro and In Silico Characterization of Lemborexant (E2006), a Novel Dual Orexin Receptor Antagonist
Carsten T. Beuckmann, Michiyuki Suzuki, Takashi Ueno, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 2, pp. 287-295
Open Access | Times Cited: 89
Accurate Prediction of GPCR Ligand Binding Affinity with Free Energy Perturbation
Francesca Deflorian, Laura Pérez‐Benito, Eelke B. Lenselink, et al.
Journal of Chemical Information and Modeling (2020) Vol. 60, Iss. 11, pp. 5563-5579
Closed Access | Times Cited: 75
Clinical pharmacology, efficacy, and safety of orexin receptor antagonists for the treatment of insomnia disorders
Clemens Muehlan, Cédric Vaillant, Isabelle Zenklusen, et al.
Expert Opinion on Drug Metabolism & Toxicology (2020) Vol. 16, Iss. 11, pp. 1063-1078
Closed Access | Times Cited: 70
Clinical specificity profile for novel rapid acting antidepressant drugs
Mauro Scala, Giuseppe Fanelli, Diana De Ronchi, et al.
International Clinical Psychopharmacology (2023) Vol. 38, Iss. 5, pp. 297-328
Open Access | Times Cited: 26
Discovery and first-time disclosure of CVN766, an exquisitely selective orexin 1 receptor antagonist
Angela Glen, Roland W. Bürli, David G. Livermore, et al.
Bioorganic & Medicinal Chemistry Letters (2024) Vol. 100, pp. 129629-129629
Open Access | Times Cited: 8
The roles of orexins in sleep/wake regulation
Michihiro Mieda
Neuroscience Research (2017) Vol. 118, pp. 56-65
Open Access | Times Cited: 73
Orexin 2 Receptor Antagonism is Sufficient to Promote NREM and REM Sleep from Mouse to Man
Anthony L. Gotter, Mark S. Forman, C. Meacham Harrell, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 72
The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468
Alexander Treiber, Ruben de Kanter, Catherine Roch, et al.
Journal of Pharmacology and Experimental Therapeutics (2017) Vol. 362, Iss. 3, pp. 489-503
Open Access | Times Cited: 69
Orexins as Novel Therapeutic Targets in Inflammatory and Neurodegenerative Diseases
Alain Couvineau, Thierry Voisin, Pascal Nicole, et al.
Frontiers in Endocrinology (2019) Vol. 10
Open Access | Times Cited: 63
The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder
Kasper Recourt, Peter de Boer, Rob Zuiker, et al.
Translational Psychiatry (2019) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Soporific effect of modified Suanzaoren Decoction on mice models of insomnia by regulating Orexin-A and HPA axis homeostasis
Yingjie Dong, Ning-Hua Jiang, Lianghui Zhan, et al.
Biomedicine & Pharmacotherapy (2021) Vol. 143, pp. 112141-112141
Open Access | Times Cited: 55
Effects of orexin receptor antagonism on human sleep architecture: A systematic review
Jacob Clark, Maddison L. Brian, Sean P. A. Drummond, et al.
Sleep Medicine Reviews (2020) Vol. 53, pp. 101332-101332
Closed Access | Times Cited: 54
Sleep dysregulation in binge eating disorder and “food addiction”: the orexin (hypocretin) system as a potential neurobiological link
Jacqueline B. Mehr, Deborah Mitchison, Hannah E. Bowrey, et al.
Neuropsychopharmacology (2021) Vol. 46, Iss. 12, pp. 2051-2061
Open Access | Times Cited: 46
Hypocretin/Orexin Receptor Pharmacology and Sleep Phases
Yu Sun, Ryan K. Tisdale, Thomas S. Kilduff
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 22-37
Open Access | Times Cited: 42
Neurobiology of the Orexin System and Its Potential Role in the Regulation of Hedonic Tone
Martin A. Katzman, Matthew P. Katzman
Brain Sciences (2022) Vol. 12, Iss. 2, pp. 150-150
Open Access | Times Cited: 30
Targeting the orexin/hypocretin system for the treatment of neuropsychiatric and neurodegenerative diseases: From animal to clinical studies
Marc Ten-Blanco, África Flores, Luigia Cristino, et al.
Frontiers in Neuroendocrinology (2023) Vol. 69, pp. 101066-101066
Open Access | Times Cited: 19
Emerging and upcoming therapies in insomnia
W.-H. Kim, Ho-Sook Kim
Translational and Clinical Pharmacology (2024) Vol. 32, Iss. 1, pp. 1-1
Open Access | Times Cited: 6
Therapeutics development for addiction: Orexin-1 receptor antagonists
David A. Perrey, Yanan Zhang
Brain Research (2018) Vol. 1731, pp. 145922-145922
Open Access | Times Cited: 55
The selective orexin-2 receptor antagonist seltorexant improves sleep: An exploratory double-blind, placebo controlled, crossover study in antidepressant-treated major depressive disorder patients with persistent insomnia
Sander Brooks, Gabriël E. Jacobs, Peter de Boer, et al.
Journal of Psychopharmacology (2019) Vol. 33, Iss. 2, pp. 202-209
Closed Access | Times Cited: 52
Translational evaluation of novel selective orexin-1 receptor antagonist JNJ-61393215 in an experimental model for panic in rodents and humans
Giacomo Salvadore, Pascal Bonaventure, Anantha Shekhar, et al.
Translational Psychiatry (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 40
Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study
Adam Savitz, Ewa Wajs, Yun Zhang, et al.
The International Journal of Neuropsychopharmacology (2021) Vol. 24, Iss. 12, pp. 965-976
Open Access | Times Cited: 40
Applications of Isosteres of Piperazine in the Design of Biologically Active Compounds: Part 2
Nicholas A. Meanwell, Olivier Loiseleur
Journal of Agricultural and Food Chemistry (2022) Vol. 70, Iss. 36, pp. 10972-11004
Closed Access | Times Cited: 27
Page 1 - Next Page

Scroll to top